On Demand Grand Rounds: Treatment approaches in perinatal depression and research into underlying pathophysiology and novel drug development
This presentation was originally reviewed on December 12, 2022, and broadcast live online on December 14, 2022, from 12:00 PM – 1:00 PM ET.
The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.
Perinatal psychiatric disorders are common, with a 12-month prevalence rate of approximately 25%. Despite the high prevalence of perinatal depression (approx. 12%), it is frequently underdiagnosed and undertreated, with resultant deleterious consequences to mothers and their offspring. This session will inform clinicians on the clinical features and pathogenesis of perinatal depression. Finally, this session will equip learners with current treatment approaches to unipolar perinatal depression and inform them about neurosteroid-based therapeutics in development.
Target Audience
This activity is intended for physicians, nurses, psychologists, social workers, counselors and other mental health professionals.
Learning Objectives
At the conclusion of this activity, attendees will be able to:
- Define three risks (maternal or neonatal) associated with untreated perinatal depression/anxiety.
- Describe three symptoms of Postnatal adaptation syndrome (PNAS) associated with maternal antenatal antidepressant use.
- Discuss the evidence for the role of neuroactive steroids in the pathophysiology of perinatal depression.
Sheppard Pratt’s Professional Education Program is pleased to provide Wednesdays at Sheppard Pratt free of charge as a public service to the mental health community. Your tax-deductible donations will help maintain the outstanding quality of this service.
Sheppard Pratt is dedicated to improving quality of life through mental health, special education, and addiction services for children, adolescents, adults and older adults. Our patient-centered treatment approach, combined with our legacy of clinical excellence, sets us apart from other health systems on both a local and national level. We have been ranked among the nation’s top psychiatric hospitals for 24 consecutive years by U. S. News & World Report. Founded in 1853 by philanthropist Moses Sheppard, Sheppard Pratt Health System still abides by its Quaker traditions and values.
Sheppard Pratt regularly hosts renowned speakers from across the country at our headquarters in Towson. We provide educational opportunities on subjects including psychiatric disorders, issues of behavioral health, systems-based change, mental and somatic co-morbidities, psychiatric effects on health and health outcomes, advances in neurobiology, and clinical developments in concepts underlying drug treatment of psychiatric disorders. We are accredited by the Accreditation Council of Continuing Medical Education, the Maryland Nurses’ Association, the Maryland Board of Psychology, the Maryland Board of Social Work, and the National Board of Certified Counselors.
Please send your contributions to:
Sheppard Pratt Professional Education Program
Wednesdays Lecture Fund
6501 North Charles Street, Baltimore, Maryland 21204
Professional Education Program: 410.938.4593
Conference Center at Sheppard Pratt: 410.938.3900
There is no commercial support for this activity.
About the speaker
Kristina Deligiannidis, MD, completed her undergraduate degrees in biology and psychology at the University of Massachusetts at Amherst. As a recipient of predoctoral intramural research training awards, she trained in molecular neuroendocrinology research at the National Institutes of Health (NIH). Dr. Deligiannidis completed additional research training at the NIH during medical school and residency in behavioral endocrinology and experimental therapeutics at the National Institute of Mental Health (NIMH). She received her medical degree from and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Medical School. After residency, she completed a visiting fellowship and further training in multimodal neuroimaging at the Massachusetts General Hospital/Martinos Center for Biomedical Imaging.
Dr. Deligiannidis joined faculty at Zucker Hillside Hospital, the Feinstein Institutes for Medical Research and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in September 2016. She is board certified by the American Board of Psychiatry and Neurology and currently serves as the director of women’s behavioral health at Zucker Hillside Hospital. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle, pregnancy/postpartum and perimenopause.
Dr. Deligiannidis actively contributes to national scientific committees and gives scientific presentations nationally and internationally. She is an associate member of the American College of Neuropsychopharmacology (ACNP), a member of the Society of Biological Psychiatry (SOBP), the American Society of Clinical Psychopharmacology (ASCP) and the Marcé Society of North America (perinatal mental health). She serves as a reviewer on more than 20 scientific journals on the national ASCP board of directors and the SOBP council, as well as on the Advisory Board/Editorial Board for the journals Acta Psychiatrica Scandinavica and Journal of Clinical Psychopharmacology. She actively serves as a federal grant reviewer for the Center for Scientific Review at NIH.
Disclosure Statements
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Kristina M. Deligiannidis, MD, reports that she is a consultant for Sage Therapeutics and consults with Brii Biosciences and GH Research. She will be discussing psychotropics and non-FDA approved therapeutics in this presentation. All relevant financial relationships have been mitigated through peer review by Sheppard Pratt of the speaker’s content and through attestation by speaker of providing clinical recommendations that are evidence-based and free from commercial bias.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Stacey Garnett, RN, MSN, Octavia Coit, MN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.
Physician Statement: Sheppard Pratt is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt is approved as a provider of nursing continuing professional development by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity provides 1.0 contact hours for nurses.
Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. Sheppard Pratt designates this educational activity for a maximum of 1.0 contact hours for Psychologists.
Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. This activity is approved for 1.0 contact hours in Category II credits for Social Workers.
Counselor Statement: Sheppard Pratt has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt is solely responsible for all aspects of the program. This activity is available for 1.0 NBCC clock hours.
Available Credit
- 1.00 ACEP NBCC clock hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Category II credits for Social Workers
- 1.00 Psychologists
- 1.00 MNA Contact Hours for Nurses
- 1.00 Participation
ON DEMAND WEBINAR: FOR BEST RESULTS WATCH USING GOOGLE CHROME
Grand Rounds: Treatment approaches in perinatal depression and research into underlying pathophysiology and novel drug development
Kristina M. Deligiannidis,MD
Associate Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research
Director, Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health
Associate Professor, Psychiatry and Obstetrics & Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Worcester, MA
Originally reviewed December 12, 2022.
Originally broadcast live December 14. 2022, from 12:00 PM - 1:00 pm ET.
Enduring Activity Credit Expiration Date: January 16, 2025.
Activity Time: One-hour recorded webinar lecture with a 15 minute evaluation process. Total Time: 1:15
TO EARN CONTINUING EDUCATION CREDIT FOR YOUR ATTENDANCE
On the OVERVIEW or REGISTER/TAKE COURSE tab, select the GREEN RECTANGLE, TAKE COURSE to begin.
Complete the Pretest and select NEXT in the bottom right corner of the screen. Use the NEXT button for best results.
The PowerPoint handout will be available for download.
After downloading the handout, select NEXT to begin and watch the video.
You may need to select play for the video to begin.
After the video follow the prompts to complete the posttest, evaluation, and attestation of credit.
Once you have completed all the components of the Course Progress bar, the certificate will be immediately downloadable.
FINANCIAL SUPPORT
There is no commercial support for this activity.
Questions? Please email cme@sheppardpratt.org.
Required Hardware/software
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Minimum Requirements
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit
Hardware/Software Specifications
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.